415 related articles for article (PubMed ID: 34806405)
1. Nimotuzumab for COVID-19: case series.
Abdo Cuza AA; Ávila JP; Martínez RM; González JJ; Aspuro GP; Gutiérrez Martínez JA; Suzarte MR; Hernández DS; Añé-Kouri AL; Ramos TC
Immunotherapy; 2021 Nov; ():. PubMed ID: 34806405
[TBL] [Abstract][Full Text] [Related]
2. Blocking EGFR with nimotuzumab: a novel strategy for COVID-19 treatment.
Londres HD; Armada JJ; Martínez AH; Abdo Cuza AA; Sánchez YH; Rodríguez AG; Figueroa SS; Llanez Gregorich EM; Torres Lahera ML; Peire FG; González TM; González YZ; Añé Kouri AL; Palomo AG; Concepción MT; Pérez LM; Luaces-Alvarez PL; Iglesias DE; Hernández DS; Suzarte MR; Ramos TC
Immunotherapy; 2022 May; 14(7):521-530. PubMed ID: 35306855
[No Abstract] [Full Text] [Related]
3. Nimotuzumab Increases the Recovery Rate of Severe and Critical COVID-19 Patients: Evaluation in the Real-World Scenario.
Diaz H; Jiménez J; Hernández A; Valdés L; Martínez A; Porto L; Hernández R; Travieso N; Jova JH; Medel L; Troche M; Gorte A; Batista D; Valls AR; Cabrera L; Domeq M; Pérez L; Lorenzo-Luaces P; Sánchez L; Saavedra D; Ramos M; Crombet T
Front Public Health; 2022; 10():948520. PubMed ID: 35937253
[TBL] [Abstract][Full Text] [Related]
4. Immune, inflammatory and prothrombotic parameters in COVID-19 patients treated with an anti EGFR antibody.
Saavedra D; Añé-Kourí AL; Gregorich EML; Mena J; Lorenzo-Luaces P; Londres HD; Martínez AH; Armada JJ; Sánchez YH; González YZ; Troche M; Medel L; Ramos M; Crombet T
Immunol Lett; 2022 Dec; 251-252():1-8. PubMed ID: 36174772
[TBL] [Abstract][Full Text] [Related]
5. Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial.
Solomón MT; Selva JC; Figueredo J; Vaquer J; Toledo C; Quintanal N; Salva S; Domíngez R; Alert J; Marinello JJ; Catalá M; Griego MG; Martell JA; Luaces PL; Ballesteros J; de-Castro N; Bach F; Crombet T
BMC Cancer; 2013 Jun; 13():299. PubMed ID: 23782513
[TBL] [Abstract][Full Text] [Related]
6. Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile.
Garrido G; Tikhomirov IA; Rabasa A; Yang E; Gracia E; Iznaga N; Fernández LE; Crombet T; Kerbel RS; Pérez R
Cancer Biol Ther; 2011 Feb; 11(4):373-82. PubMed ID: 21150278
[TBL] [Abstract][Full Text] [Related]
7. Nimotuzumab promotes radiosensitivity of EGFR-overexpression esophageal squamous cell carcinoma cells by upregulating IGFBP-3.
Zhao L; He LR; Xi M; Cai MY; Shen JX; Li QQ; Liao YJ; Qian D; Feng ZZ; Zeng YX; Xie D; Liu MZ
J Transl Med; 2012 Dec; 10():249. PubMed ID: 23232108
[TBL] [Abstract][Full Text] [Related]
8. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.
Chong DQ; Toh XY; Ho IA; Sia KC; Newman JP; Yulyana Y; Ng WH; Lai SH; Ho MM; Dinesh N; Tham CK; Lam PY
BMC Cancer; 2015 Apr; 15():255. PubMed ID: 25886314
[TBL] [Abstract][Full Text] [Related]
9. ¹¹¹In-Bn-DTPA-nimotuzumab with/without modification with nuclear translocation sequence (NLS) peptides: an Auger electron-emitting radioimmunotherapeutic agent for EGFR-positive and trastuzumab (Herceptin)-resistant breast cancer.
Fasih A; Fonge H; Cai Z; Leyton JV; Tikhomirov I; Done SJ; Reilly RM
Breast Cancer Res Treat; 2012 Aug; 135(1):189-200. PubMed ID: 22736376
[TBL] [Abstract][Full Text] [Related]
10. A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC).
Kim SH; Shim HS; Cho J; Jeong JH; Kim SM; Hong YK; Sung JH; Ha SJ; Kim HR; Chang H; Kim JH; Tania C; Cho BC
Lung Cancer; 2013 Mar; 79(3):270-5. PubMed ID: 23261229
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: a SENDO Foundation study.
Rojo F; Gracias E; Villena N; Cruz T; Corominas JM; Corradino I; Cedeño M; Campas C; Osorio M; Iznaga N; Bellosillo B; Rovira A; Marsoni S; Gascon P; Serrano S; Sessa C; Crombet T; Albanell J
Clin Cancer Res; 2010 Apr; 16(8):2474-82. PubMed ID: 20371675
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic potential of nimotuzumab PEGylated-maytansine antibody drug conjugates against EGFR positive xenograft.
Hartimath SV; El-Sayed A; Makhlouf A; Bernhard W; Gonzalez C; Hill W; Parada AC; Barreto K; Geyer CR; Fonge H
Oncotarget; 2019 Feb; 10(10):1031-1044. PubMed ID: 30800216
[TBL] [Abstract][Full Text] [Related]
13. EGFR targeting monoclonal antibody combines with an mTOR inhibitor and potentiates tumor inhibition by acting on complementary signaling hubs.
James R; Vishwakarma S; Chivukula IV; Basavaraj C; Melarkode R; Montero E; Nair P
Cancer Med; 2012 Oct; 1(2):114-27. PubMed ID: 23342262
[TBL] [Abstract][Full Text] [Related]
14. Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open-label, phase IIb, 5-year study in Indian patients.
Reddy BK; Lokesh V; Vidyasagar MS; Shenoy K; Babu KG; Shenoy A; Naveen T; Joseph B; Bonanthaya R; Nanjundappa ; Bapsy PP; Loknatha ; Shetty J; Prasad K; Tanvir Pasha CR
Oral Oncol; 2014 May; 50(5):498-505. PubMed ID: 24613543
[TBL] [Abstract][Full Text] [Related]
15. Treatment of malignant, non-resectable, epithelial origin esophageal tumours with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy.
Ramos-Suzarte M; Lorenzo-Luaces P; Lazo NG; Perez ML; Soriano JL; Gonzalez CE; Hernadez IM; Albuerne YÁ; Moreno BP; Alvarez ES; Callejo IP; Alert J; Martell JA; Gonzalez YS; Gonzalez YS; Astudillo de la Vega H; Ruiz-Garcia EB; Ramos TC
Cancer Biol Ther; 2012 Jun; 13(8):600-5. PubMed ID: 22555809
[TBL] [Abstract][Full Text] [Related]
16. [Nimotuzumab Combined with Chemotherapy as Second- or Later-line
in the Treatment of Advanced Lung Squamous Cell Carcinoma].
Luo Y; Li J; Wang Y; Hao X; Qu F
Zhongguo Fei Ai Za Zhi; 2016 Oct; 19(10):665-669. PubMed ID: 27760595
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous Imaging and Therapy Using Epitope-Specific Anti-Epidermal Growth Factor Receptor (EGFR) Antibody Conjugates.
Tikum AF; Nambisan AK; Ketchemen JP; Babeker H; Khan MN; Torlakovic EE; Fonge H
Pharmaceutics; 2022 Sep; 14(9):. PubMed ID: 36145664
[TBL] [Abstract][Full Text] [Related]
18. Combining Nimotuzumab With Chemotherapy for Patients With Locally Advanced and Intermediate-Stage Nasopharyngeal Cancer: A Retrospective Comparison Study Using Five-Year, Real-World Survival Data.
Rachman A; Sari SR; Munandar A; Adham M; Hutajulu SH
Cureus; 2023 Nov; 15(11):e48804. PubMed ID: 38098929
[TBL] [Abstract][Full Text] [Related]
19. Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients.
Mazorra Z; Lavastida A; Concha-Benavente F; Valdés A; Srivastava RM; García-Bates TM; Hechavarría E; González Z; González A; Lugiollo M; Cuevas I; Frómeta C; Mestre BF; Barroso MC; Crombet T; Ferris RL
Front Pharmacol; 2017; 8():382. PubMed ID: 28674498
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and normal tissue toxicity of Auger electron (AE) radioimmunotherapy (RIT) with [
Chan C; Fonge H; Lam K; Reilly RM
Nucl Med Biol; 2020; 80-81():37-44. PubMed ID: 31706737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
